{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:07:20Z","timestamp":1790968040534,"version":"4.1.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,11,16]],"date-time":"2010-11-16T00:00:00Z","timestamp":1289865600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. of Cardiovasc. Trans. Res."],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1007\/s12265-010-9230-6","type":"journal-article","created":{"date-parts":[[2010,11,15]],"date-time":"2010-11-15T20:05:43Z","timestamp":1289851543000},"page":"704-716","source":"Crossref","is-referenced-by-count":14,"title":["Translating Nucleic Acid Aptamers to Antithrombotic Drugs in Cardiovascular Medicine"],"prefix":"10.1007","volume":"3","author":[{"given":"Thomas J.","family":"Povsic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce A.","family":"Sullenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven L.","family":"Zelenkofske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Rusconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard C.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,11,16]]},"reference":[{"key":"9230_CR1","doi-asserted-by":"crossref","first-page":"670S","DOI":"10.1378\/chest.08-0691","volume":"133","author":"RA Harrington","year":"2008","unstructured":"Harrington, R. A., Becker, R. C., Cannon, C. P., Gutterman, D., Lincoff, A. M., Popma, J. J., et al. (2008). Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes*. Chest, 133, 670S\u2013707S. doi: 10.1378\/chest.08-0691 .","journal-title":"Chest"},{"key":"9230_CR2","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., et al. (2007). Prasugrel versus clopidogrel in patients with acute coronary syndromes. The New England Journal of Medicine, 357, 2001\u20132015. doi: 10.1056\/NEJMoa0706482 .","journal-title":"The New England Journal of Medicine"},{"key":"9230_CR3","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.298.21.2497","volume":"298","author":"GW Stone","year":"2007","unstructured":"Stone, G. W., Ware, J. H., Bertrand, M. E., Lincoff, A. M., Moses, J. W., Ohman, E. M., et al. (2007). Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the acuity trial. JAMA, 298, 2497\u20132506. doi: 10.1001\/jama.298.21.2497 .","journal-title":"JAMA"},{"key":"9230_CR4","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(09)60230-0","volume":"373","author":"RC Becker","year":"2009","unstructured":"Becker, R. C., Moliterno, D. J., Jennings, L. K., Pieper, K. S., Pei, J., Niederman, A., et al. (2009). Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet, 373, 919\u2013928.","journal-title":"Lancet"},{"key":"9230_CR5","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1126\/science.2200121","volume":"249","author":"C Tuerk","year":"1990","unstructured":"Tuerk, C., & Gold, L. (1990). Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage t4 DNA polymerase. Science, 249, 505\u2013510.","journal-title":"Science"},{"key":"9230_CR6","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/346818a0","volume":"346","author":"AD Ellington","year":"1990","unstructured":"Ellington, A. D., & Szostak, J. W. (1990). In vitro selection of RNA molecules that bind specific ligands. Nature, 346, 818\u2013822.","journal-title":"Nature"},{"key":"9230_CR7","first-page":"391","volume":"288","author":"E Dausse","year":"2005","unstructured":"Dausse, E., Cazenave, C., Rayner, B., & Toulme, J. J. (2005). In vitro selection procedures for identifying DNA and RNA aptamers targeted to nucleic acids and proteins. Methods in Molecular Biology, 288, 391\u2013410.","journal-title":"Methods in Molecular Biology"},{"key":"9230_CR8","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/cbic.200300648","volume":"4","author":"M Rimmele","year":"2003","unstructured":"Rimmele, M. (2003). Nucleic acid aptamers as tools and drugs: Recent developments. Chembiochem, 4, 963\u2013971. doi: 10.1002\/cbic.200300648 .","journal-title":"Chembiochem"},{"key":"9230_CR9","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1126\/science.1857967","volume":"253","author":"WA Pieken","year":"1991","unstructured":"Pieken, W. A., Olsen, D. B., Benseler, F., Aurup, H., & Eckstein, F. (1991). Kinetic characterization of ribonuclease-resistant 2\u2032-modified hammerhead ribozymes. Science, 253, 314\u2013317.","journal-title":"Science"},{"key":"9230_CR10","doi-asserted-by":"crossref","first-page":"25702","DOI":"10.1074\/jbc.270.43.25702","volume":"270","author":"L Beigelman","year":"1995","unstructured":"Beigelman, L., McSwiggen, J. A., Draper, K. G., Gonzalez, C., Jensen, K., Karpeisky, A. M., et al. (1995). Chemical modification of hammerhead ribozymes. Catalytic activity and nuclease resistance. The Journal of Biological Chemistry, 270, 25702\u201325708.","journal-title":"The Journal of Biological Chemistry"},{"key":"9230_CR11","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1146\/annurev.med.56.062904.144915","volume":"56","author":"SM Nimjee","year":"2005","unstructured":"Nimjee, S. M., Rusconi, C. P., & Sullenger, B. A. (2005). Aptamers: An emerging class of therapeutics. Annual Review of Medicine, 56, 555\u2013583. doi: 10.1146\/annurev.med.56.062904.144915 .","journal-title":"Annual Review of Medicine"},{"key":"9230_CR12","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1146\/annurev.pharmtox.010909.105547","volume":"50","author":"PR Bouchard","year":"2010","unstructured":"Bouchard, P. R., Hutabarat, R. M., & Thompson, K. M. (2010). Discovery and development of therapeutic aptamers. Annual Review of Pharmacology and Toxicology, 50, 237\u2013257. doi: 10.1146\/annurev.pharmtox.010909.105547 .","journal-title":"Annual Review of Pharmacology and Toxicology"},{"key":"9230_CR13","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1055\/s-0037-1614126","volume":"84","author":"CP Rusconi","year":"2000","unstructured":"Rusconi, C. P., Yeh, A., Lyerly, H. K., Lawson, J. H., & Sullenger, B. A. (2000). Blocking the initiation of coagulation by RNA aptamers to factor VIIa. Thromb Haemost, 84, 841\u2013848.","journal-title":"Thromb Haemost"},{"key":"9230_CR14","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1073\/pnas.92.6.2355","volume":"92","author":"JA Doudna","year":"1995","unstructured":"Doudna, J. A., Cech, T. R., & Sullenger, B. A. (1995). Selection of an RNA molecule that mimics a major autoantigenic epitope of human insulin receptor. Proceedings of the National Academy of Sciences of the United States of America, 92, 2355\u20132359.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"9230_CR15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nbt0197-41","volume":"15","author":"SW Lee","year":"1997","unstructured":"Lee, S. W., & Sullenger, B. A. (1997). Isolation of a nuclease-resistant decoy RNA that can protect human acetylcholine receptors from myasthenic antibodies. Nature Biotechnology, 15, 41\u201345. doi: 10.1038\/nbt0197-41 .","journal-title":"Nature Biotechnology"},{"key":"9230_CR16","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nature00963","volume":"419","author":"CP Rusconi","year":"2002","unstructured":"Rusconi, C. P., Scardino, E., Layzer, J., Pitoc, G. A., Ortel, T. L., Monroe, D., et al. (2002). RNA aptamers as reversible antagonists of coagulation factor IXa. Nature, 419, 90\u201394.","journal-title":"Nature"},{"key":"9230_CR17","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nbt1023","volume":"22","author":"CP Rusconi","year":"2004","unstructured":"Rusconi, C. P., Roberts, J. D., Pitoc, G. A., Nimjee, S. M., White, R. R., Quick, G., et al. (2004). Antidote-mediated control of an anticoagulant aptamer in vivo. Nature Biotechnology, 22, 1423\u20131428.","journal-title":"Nature Biotechnology"},{"key":"9230_CR18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.tcm.2005.01.002","volume":"15","author":"SM Nimjee","year":"2005","unstructured":"Nimjee, S. M., Rusconi, C. P., Harrington, R. A., & Sullenger, B. A. (2005). The potential of aptamers as anticoagulants. Trends in Cardiovascular Medicine, 15, 41\u201345.","journal-title":"Trends in Cardiovascular Medicine"},{"key":"9230_CR19","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/j.1538-7836.2008.02932.x","volume":"6","author":"MY Chan","year":"2008","unstructured":"Chan, M. Y., Rusconi, C. P., Alexander, J. H., Tonkens, R. M., Harrington, R. A., & Becker, R. C. (2008). A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor. Journal of Thrombosis and Haemostasis, 6, 789\u2013796.","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"9230_CR20","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1038\/nm.1990","volume":"15","author":"S Oney","year":"2009","unstructured":"Oney, S., Lam, R. T., Bompiani, K. M., Blake, C. M., Quick, G., Heidel, J. D., et al. (2009). Development of universal antidotes to control aptamer activity. Nature Medicine, 15, 1224\u20131228.","journal-title":"Nature Medicine"},{"key":"9230_CR21","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1182\/blood.V86.5.1794.bloodjournal8651794","volume":"86","author":"M Hoffman","year":"1995","unstructured":"Hoffman, M., Monroe, D. M., Oliver, J. A., & Roberts, H. R. (1995). Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation. Blood, 86, 1794\u20131801.","journal-title":"Blood"},{"key":"9230_CR22","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/00001721-199606000-00005","volume":"7","author":"DM Monroe","year":"1996","unstructured":"Monroe, D. M., Hoffman, M., & Roberts, H. R. (1996). Transmission of a procoagulant signal from tissue factor-bearing cells to platelets. Bood Coagulation and Fibrinolysis, 7, 459\u2013464.","journal-title":"Bood Coagulation and Fibrinolysis"},{"key":"9230_CR23","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1161\/01.ATV.0000259363.91070.f1","volume":"27","author":"EL Howard","year":"2007","unstructured":"Howard, E. L., Becker, K. C. D., Rusconi, C. P., & Becker, R. C. (2007). Factor IXa inhibitors as novel anticoagulants. Arteriosclerosis, Thrombosis, and Vascular Biology, 27, 722\u2013727. doi: 10.1161\/01.ATV.0000259363.91070.f1 .","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"9230_CR24","first-page":"52","volume":"108","author":"A Sramek","year":"2003","unstructured":"Sramek, A., Kriek, M., & Rosendaal, F. (2003). Decreased mortality of ischaemic heart disease among carriers of haemophilia. Blood, 108, 52\u201366.","journal-title":"Blood"},{"key":"9230_CR25","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1538-7836.2008.03201.x","volume":"7","author":"A Tuinenburg","year":"2009","unstructured":"Tuinenburg, A., Mauser-Bunschoten, E., Verhaar, M., Biesma, D., & Schutgens, R. (2009). Cardiovascular disease in patients with hemophilia. Journal of Thrombosis and Haemostasis, 7, 247\u2013254.","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"9230_CR26","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/S0140-6736(03)13405-8","volume":"361","author":"PHB Bolton-Maggs","year":"2003","unstructured":"Bolton-Maggs, P. H. B., & Pasi, K. J. (2003). Haemophilias a and b. Lancet, 361, 1801\u20131809.","journal-title":"Lancet"},{"key":"9230_CR27","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1161\/CIRCULATIONAHA.106.668434","volume":"114","author":"CK Dyke","year":"2006","unstructured":"Dyke, C. K., Steinhubl, S. R., Kleiman, N. S., Cannon, R. O., Aberle, L. G., Lin, M., et al. (2006). First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: A phase 1a pharmacodynamic evaluation of a drug\u2013antidote pair for the controlled regulation of factor IXa activity. Circulation, 114, 2490\u20132497. doi: 10.1161\/circulationaha.106.668434 .","journal-title":"Circulation"},{"key":"9230_CR28","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ymthe.2006.04.006","volume":"14","author":"SM Nimjee","year":"2006","unstructured":"Nimjee, S. M., Keys, J. R., Pitoc, G. A., Quick, G., Rusconi, C. P., & Sullenger, B. A. (2006). A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery. Molecular Therapy, 14, 408\u2013415.","journal-title":"Molecular Therapy"},{"key":"9230_CR29","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1161\/CIRCULATIONAHA.107.745687","volume":"117","author":"MY Chan","year":"2008","unstructured":"Chan, M. Y., Cohen, M. G., Dyke, C. K., Myles, S. K., Aberle, L. G., Lin, M., et al. (2008). Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. Circulation, 117, 2865\u20132874. doi: 10.1161\/circulationaha.107.745687 .","journal-title":"Circulation"},{"key":"9230_CR30","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1161\/CIRCULATIONAHA.109.927756","volume":"122","author":"MG Cohen","year":"2010","unstructured":"Cohen, M. G., Purdy, D. A., Rossi, J. S., Grinfeld, L. R., Myles, S. K., Aberle, L. G., et al. (2010). First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous intervention. Circulation, 122, 614\u2013622.","journal-title":"Circulation"},{"key":"9230_CR31","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1124\/jpet.104.078790","volume":"313","author":"D McLennan","year":"2005","unstructured":"McLennan, D., Porter, C., Edwards, G., Martin, S., Heatherington, A., & Charman, S. (2005). Lymphatic absorption is the primary contributor to the systemic availability of epoetin alfa following subcutaneous administration to sheep. The Journal of Pharmacology and Experimental Therapeutics, 313, 345\u2013351.","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"9230_CR32","doi-asserted-by":"crossref","first-page":"A172.E1618","DOI":"10.1016\/S0735-1097(10)61619-1","volume":"55","author":"CP Rusconi","year":"2010","unstructured":"Rusconi, C. P., Kornbrust, D., & Zelenkofske, S. L. (2010). Subcutaneous FIXa inhibitor provides prolonged anticoagulation: the first successful subcutaneous application of an aptamer. Journal of the American College of Cardiology, 55, A172.E1618.","journal-title":"Journal of the American College of Cardiology"},{"key":"9230_CR33","unstructured":"Zelenkofske, S., Rusconi, C. P., Damiento, C., Wargin, W., Medlock, M., Becker, R.C. (2010) Subcutaneous rb006: A direct FIXa inhibitor provides prolonged anticoagulation with rapid reversal: The first clinical experience with the reg2 system. Atherothrombosis and Vascular Biology Meeting, San Francisco, CA, April 5, 2010."},{"key":"9230_CR34","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1161\/ATVBAHA.110.203117","volume":"30","author":"JW Eikelboom","year":"2010","unstructured":"Eikelboom, J. W., Zelenkofske, S. L., & Rusconi, C. P. (2010). Coagulation factor IXa as a target for treatment and prophylaxis of venous thromboembolism. Arteriosclerosis, Thrombosis, and Vascular Biology, 30, 382\u2013387. doi: 10.1161\/atvbaha.110.203117 .","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"9230_CR35","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1007\/s00018-006-6219-z","volume":"63","author":"A Schwienhorst","year":"2006","unstructured":"Schwienhorst, A. (2006). Direct thrombin inhibitors\u2014a survey of recent developments. Cellular and Molecular Life Sciences, 63, 2773\u20132791.","journal-title":"Cellular and Molecular Life Sciences"},{"key":"9230_CR36","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/355564a0","volume":"355","author":"L Bock","year":"1992","unstructured":"Bock, L., Griffin, L., Latham, J., Vermaas, E., & Toole, J. (1992). Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature, 355, 564\u2013566.","journal-title":"Nature"},{"key":"9230_CR37","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/0003-4975(94)92206-3","volume":"58","author":"AJ DeAnda","year":"1994","unstructured":"DeAnda, A. J., Coutre, S., Moon, M., Vial, C., Griffin, L., Law, V., et al. (1994). Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass. The Annals of Thoracic Surgery, 58, 344\u2013350.","journal-title":"The Annals of Thoracic Surgery"},{"key":"9230_CR38","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1093\/nar\/gkp1148","volume":"38","author":"MCR Buff","year":"2010","unstructured":"Buff, M. C. R., Schafer, F., Wulffen, B., Muller, J., Potzsch, B., Heckel, A., et al. (2010). Dependence of aptamer activity on opposed terminal extensions: Improvement of light-regulation efficiency. Nucleic Acids Research, 38, 2111\u20132118. doi: 10.1093\/nar\/gkp1148 .","journal-title":"Nucleic Acids Research"},{"key":"9230_CR39","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1002\/cbic.200700535","volume":"8","author":"J Muller","year":"2007","unstructured":"Muller, J., Wulffen, B., Potzsch, B., & Mayer, G. (2007). Multidomain targeting generates a high-affinity thrombin-inhibiting bivalent aptamer. Chembiochem, 8, 2223\u20132226.","journal-title":"Chembiochem"},{"key":"9230_CR40","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.febslet.2004.04.087","volume":"568","author":"ML Jeter","year":"2004","unstructured":"Jeter, M. L., Ly, L. V., Fortenberry, Y. M., Whinna, H. C., White, R. R., Rusconi, C. P., et al. (2004). RNA aptamer to thrombin binds anion-binding exosite-2 and alters protease inhibition by heparin-binding serpins. FEBS Letters, 568, 10\u201314.","journal-title":"FEBS Letters"},{"key":"9230_CR41","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1261\/rna.1239308","volume":"14","author":"SB Long","year":"2008","unstructured":"Long, S. B., Long, M. B., White, R. R., & Sullenger, B. A. (2008). Crystal structure of an RNA aptamer bound to thrombin. RNA, 14, 2504\u20132525.","journal-title":"RNA"},{"key":"9230_CR42","doi-asserted-by":"crossref","first-page":"17651","DOI":"10.1016\/S0021-9258(17)46749-4","volume":"268","author":"K Padmanabhan","year":"1993","unstructured":"Padmanabhan, K., Padmanabhan, K. P., Ferrara, J. D., Sadler, J. E., & Tulinsky, A. (1993). The structure of alpha-thrombin inhibited by a 15-mer single-stranded DNA aptamer. The Journal of Biological Chemistry, 268, 17651\u201317654.","journal-title":"The Journal of Biological Chemistry"},{"key":"9230_CR43","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1107\/S0907444995013977","volume":"52","author":"K Padmanabhan","year":"1996","unstructured":"Padmanabhan, K., & Tulinsky, A. (1996). An ambiguous structure of a DNA 15-mer thrombin complex. Acta Crystallographica. Section D: Biological Crystallography, 52, 272\u2013282.","journal-title":"Acta Crystallographica. Section D: Biological Crystallography"},{"key":"9230_CR44","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1261\/rna.1240109","volume":"15","author":"SM Nimjee","year":"2009","unstructured":"Nimjee, S. M., Oney, S., Volovyk, Z., Bompiani, K. M., Long, S. B., Hoffman, M., et al. (2009). Synergistic effect of aptamers that inhibit exosites 1 and 2 on thrombin. RNA, 15, 2105\u20132111.","journal-title":"RNA"},{"key":"9230_CR45","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1182\/blood-2008-10-165621","volume":"113","author":"SF Meyer De","year":"2009","unstructured":"De Meyer, S. F., Deckmyn, H., & Vanhoorelbeke, K. (2009). von Willebrand factor to the rescue. Blood, 113, 5049\u20135057. doi: 10.1182\/blood-2008-10-165621 .","journal-title":"Blood"},{"key":"9230_CR46","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1146\/annurev.med.56.082103.104713","volume":"56","author":"J Sadler","year":"2005","unstructured":"Sadler, J. (2005). New concepts in von Willebrand disease. Annual Review of Medicine, 56, 173\u2013191.","journal-title":"Annual Review of Medicine"},{"key":"9230_CR47","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1111\/j.1538-7836.2005.01369.x","volume":"3","author":"J Sadler","year":"2005","unstructured":"Sadler, J. (2005). von Willebrand factor: Two sides of a coin. Journal of Thrombosis and Haemostasis, 3, 1702\u20131709.","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"9230_CR48","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1046\/j.1538-7836.2003.00260.x","volume":"1","author":"ZM Ruggeri","year":"2003","unstructured":"Ruggeri, Z. M. (2003). von Willebrand factor, platelets and endothelial cell interactions. Journal of Thrombosis and Jaemostasis, 1, 1335\u20131342.","journal-title":"Journal of Thrombosis and Jaemostasis"},{"key":"9230_CR49","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1089\/oli.2007.0089","volume":"17","author":"S Oney","year":"2007","unstructured":"Oney, S., Nimjee, S. M., Layzer, J., Que-Gewirth, N., Ginsburg, D., Becker, R. C., et al. (2007). Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamers. Oligonucleotides, 17, 265\u2013274. doi: 10.1089\/oli.2007.0089 .","journal-title":"Oligonucleotides"},{"key":"9230_CR50","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1161\/CIRCULATIONAHA.107.724864","volume":"116","author":"JC Gilbert","year":"2007","unstructured":"Gilbert, J. C., DeFeo-Fraulini, T., Hutabarat, R. M., Horvath, C. J., Merlino, P. G., Marsh, H. N., et al. (2007). First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation, 116, 2678\u20132686. doi: 10.1161\/circulationaha.107.724864 .","journal-title":"Circulation"},{"key":"9230_CR51","doi-asserted-by":"crossref","unstructured":"Firbas, Cs., Jilma, B., Wagner, P. G., Hutabarat, R., Schaub, R. G., Gilbert, J. C., Knoebl, P. (2008) Anti von Willebrand factor aptamer arc 1779 for refractory thrombotic thrombocytopenic purpura. ASH Annual Meeting Abstracts 112, p. 2298","DOI":"10.1182\/blood.V112.11.2298.2298"},{"key":"9230_CR52","unstructured":"Ima, B. J., Jilma, P., Paulinska, P., Gilbert, J. C., Hutabarat, R., Wagner, T., Knoebl, P. (2008) Proof of concept for the anti von Willebrand factor aptamer in patients with relapsing thrombotic thrombocytopenic purpura (TTP). ASH Annual Meeting Abstracts 112, p. 2290"},{"key":"9230_CR53","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1182\/blood.V96.5.1798","volume":"96","author":"M Jandrot-Perrus","year":"2000","unstructured":"Jandrot-Perrus, M., Busfield, S., Lagrue, A.-H., Xiong, X., Debili, N., Chickering, T., et al. (2000). Cloning, characterization, and functional studies of human and mouse glycoprotein VI: A platelet-specific collagen receptor from the immunoglobulin superfamily. Blood, 96, 1798\u20131807.","journal-title":"Blood"},{"key":"9230_CR54","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1080\/09537100701609027","volume":"19","author":"SM Jung","year":"2008","unstructured":"Jung, S. M., Takemura, Y., Imamura, Y., Hayashi, T., Adachi, E., & Moroi, M. (2008). Collagen-type specificity of glycoprotein VI as a determinant of platelet adhesion. Platelets, 19, 32\u201342.","journal-title":"Platelets"},{"key":"9230_CR55","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2141.2007.06799.x","volume":"139","author":"JF Arthur","year":"2007","unstructured":"Arthur, J. F., Dunkley, S., & Andrews, R. K. (2007). Platelet glycoprotein VI-related clinical defects. British Journal Haematology, 139, 363\u2013372.","journal-title":"British Journal Haematology"},{"key":"9230_CR56","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.1016\/j.thromres.2010.01.005","volume":"125","author":"B Bigalke","year":"2010","unstructured":"Bigalke, B., Haap, M., Stellos, K., Geisler, T., Seizer, P., Kremmer, E., et al. (2010). Platelet glycoprotein VI (GPVI) for early identification of acute coronary syndrome in patients with chest pain. Thrombosis Research, 125, e184\u2013e189.","journal-title":"Thrombosis Research"},{"key":"9230_CR57","doi-asserted-by":"crossref","unstructured":"Bigalke B, Stellos K, Geisler T, Kremmer E, Seizer P, May AE, Lindemann S, Gawaz M (2009) Glycoprotein VI for diagnosis of acute coronary syndrome when ECG is ambiguous. Int J Cardiol. doi: 10.1016\/j.ijcard.2009.12.026","DOI":"10.1016\/j.ijcard.2009.12.026"},{"key":"9230_CR58","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00392-009-0109-y","volume":"99","author":"B Bigalke","year":"2010","unstructured":"Bigalke, B., Stellos, K., Geisler, T., Lindemann, S., May, A., & Gawaz, M. (2010). Glycoprotein VI as a prognostic biomarker for cardiovascular death in patients with symptomatic coronary artery disease. Clinical Research in Cardiology, 99, 227\u2013233.","journal-title":"Clinical Research in Cardiology"},{"key":"9230_CR59","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.2337\/diabetes.53.8.2117","volume":"53","author":"N Cabeza","year":"2004","unstructured":"Cabeza, N., Li, Z., Schulz, C., Kremmer, E., Massberg, S., Bultmann, A., et al. (2004). Surface expression of collagen receptor Fc receptor-\u03b3\/glycoprotein VI is enhanced on platelets in type 2 diabetes and mediates release of CD40 ligand and activation of endothelial cells. Diabetes, 53, 2117\u20132121. doi: 10.2337\/diabetes.53.8.2117 .","journal-title":"Diabetes"},{"key":"9230_CR60","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1161\/01.ATV.0000259359.52265.62","volume":"27","author":"CV Denis","year":"2007","unstructured":"Denis, C. V., & Wagner, D. D. (2007). Platelet adhesion receptors and their ligands in mouse models of thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 27, 728\u2013739. doi: 10.1161\/01.atv.0000259359.52265.62 .","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"9230_CR61","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1160\/TH04-10-0660","volume":"93","author":"M Gawaz","year":"2005","unstructured":"Gawaz, M., Konrad, I., Hauser, A. I., Sauer, S., Li, Z., Wester, J.-J., et al. (2005). Non-invasive imaging of blycoprotein VI binding to injured arterial lesions. Thrombosis and Haemostasis, 93, 910\u2013913.","journal-title":"Thrombosis and Haemostasis"},{"key":"9230_CR62","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1096\/fj.04-2748com","volume":"19","author":"S Penz","year":"2005","unstructured":"Penz, S., Reininger, A. J., Brandl, R., Goyal, P., Rabie, T., Bernlochner, I., et al. (2005). Human atheromatous plaques stimulate thrombus formation by activating platelet glycoprotein VI. The FASEB Journal, 19, 898\u2013909. doi: 10.1096\/fj.04-2748com .","journal-title":"The FASEB Journal"},{"key":"9230_CR63","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2174\/187152906778249536","volume":"6","author":"SF Meyer De","year":"2006","unstructured":"De Meyer, S. F., Vanhoorelbeke, K., Ulrichts, H., Staelens, S., Feys, H., Salles, I., et al. (2006). Development of monoclonal antibodies that inhibit platelet adhesion or aggregation as potential anti-thrombotic drugs. Cardiovascular and Haematologic Disorders-Drug Targets, 6, 191\u2013207.","journal-title":"Cardiovascular and Haematologic Disorders-Drug Targets"},{"key":"9230_CR64","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/j.1538-7836.2008.02976.x","volume":"6","author":"P Ohlmann","year":"2008","unstructured":"Ohlmann, P., Hechler, B., Ravanat, C., Loyau, S., Herrenschmidt, N., Wanert, F., et al. (2008). Ex vivo inhibition of thrombus formation by an anti-glycoprotein VI Fab fragment in non-human primates without modification of glycoprotein VI expression. Thrombosis and Haemostasis, 6, 1003\u20131011.","journal-title":"Thrombosis and Haemostasis"},{"key":"9230_CR65","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1096\/fj.03-0464fje","volume":"18","author":"S Massberg","year":"2004","unstructured":"Massberg, S., Konrad, I., Bultmann, A., Schulz, C., Munch, G., Peluso, M., et al. (2004). Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo. FASEB J., 18, 397\u2013399. doi: 10.1096\/fj.03-0464fje .","journal-title":"FASEB J."}],"container-title":["Journal of Cardiovascular Translational Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-010-9230-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12265-010-9230-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-010-9230-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T15:31:15Z","timestamp":1636817475000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12265-010-9230-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,16]]},"references-count":65,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["9230"],"URL":"https:\/\/doi.org\/10.1007\/s12265-010-9230-6","relation":{},"ISSN":["1937-5387","1937-5395"],"issn-type":[{"value":"1937-5387","type":"print"},{"value":"1937-5395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,16]]}}}